Today, Coherus Biosciences filed four petitions for inter partes review of Abbvie’s U.S. Patent 9,085,619 (IPR2017-00822, IPR2017-00823, IPR2017-00826, and IPR2017-00827). According to the petitions, the patent is drawn to formulations of adalimumab, commercially available under the brand-name Humira®.
Coherus already has three instituted IPR proceedings on patents related to adalimumab, IPR2016-00172, IPR2016-00188, and IPR2016-00189. These proceedings are scheduled for oral hearing on February 16, 2017.
The newly filed petitions and other important IPR documents related to biologics are posted on our IPR tracker page.